Medit today announced that there is an ongoing lawsuit in Germany in relation to European Patent no. 2 568 870 B1.

The Regional Court of Duesseldorf in Germany rendered a judgment on January 9, 2020 (docket number 4c O 11/19), holding that Medit's successful scanner "i500" infringes the German part of the European EP 2 568 870 of 3Shape A/S. The court has interpreted the patent very broadly. Medit disagrees with the outcome and will appeal the first instance decision before the Duesseldorf Court of Appeal. Also, the German court system does not fully take into account the validity of the patent. Medit has challenged that validity of the patent in a nullity action. With the interpretation now applied by the infringement court, Medit is convinced to show that the patent is not valid, so that any of 3Shape's claims are in fact baseless.

Medit also clarifies that the judgment only relates to Germany and has no effect in other countries. The judgment only pertains to Medit and partner companies are not a party to the case. As 3Shape made the conscious decision to only sue Medit, the judgment does not affect partners who are therefore not obligated to do anything ordered in the proceedings against Medit.

Regardless of the final outcome of the case, Medit believes that it will not have any impact on their product supply as the company will, in the course of January 2020, be introducing a new software update with the same excellent features as always to overcome any patent concerns addressed in the first instance decision.

Medit has been developing 3D scanning technologies for more than 20 years, taking the knowledge gained in the industrial field to expand into the dental field. The company's aim is to provide a truly open system for users in the dental industry, giving dental practitioners the freedom and flexibility to work with different software providers and partners. Medit will not waver in its desire to continue developing more innovative solutions to make digital dentistry more accessible to everyone.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.